152 related articles for article (PubMed ID: 27465548)
1. DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.
Cirauqui B; Margelí M; Quiroga V; Quer A; Karachaliou N; Chaib I; Ramírez JL; Muñoz A; Pollán C; Planas I; Drozdowsky A; Rosell R
Tumour Biol; 2016 Oct; 37(10):13435-13443. PubMed ID: 27465548
[TBL] [Abstract][Full Text] [Related]
2. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.
Pavón MA; Parreño M; León X; Sancho FJ; Céspedes MV; Casanova I; Lopez-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Int J Cancer; 2008 Sep; 123(5):1068-79. PubMed ID: 18546291
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
Bonanno L; Costa C; Majem M; Sanchez JJ; Gimenez-Capitan A; Rodriguez I; Vergnenegre A; Massuti B; Favaretto A; Rugge M; Pallares C; Taron M; Rosell R
Oncotarget; 2013 Oct; 4(10):1572-81. PubMed ID: 24197907
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
[TBL] [Abstract][Full Text] [Related]
5. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome.
Koukourakis MI; Giatromanolaki A; Kakolyris S; Sivridis E; Georgoulias V; Funtzilas G; Hickson ID; Gatter KC; Harris AL
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):27-36. PubMed ID: 11316543
[TBL] [Abstract][Full Text] [Related]
6. Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Wei B; Han Q; Xu L; Zhang X; Zhu J; Wan L; Jin Y; Qian Z; Wu J; Gao Y; Zhou J; Chen X
BMC Cancer; 2015 Apr; 15():331. PubMed ID: 25925371
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of hypoxia in advanced head and neck cancer after treatment with hyperfractionated radio-chemotherapy and hypoxia modification.
Clavo B; Robaina F; Fiuza D; Ruiz A; Lloret M; Rey-Baltar D; Llontop P; Riveros A; Rivero J; Castañeda F; Quintero S; Santana-Rodríguez N
Clin Transl Oncol; 2017 Apr; 19(4):419-424. PubMed ID: 27527617
[TBL] [Abstract][Full Text] [Related]
8. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
[TBL] [Abstract][Full Text] [Related]
9. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
[TBL] [Abstract][Full Text] [Related]
10. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
McLaughlin M; Barker HE; Khan AA; Pedersen M; Dillon M; Mansfield DC; Patel R; Kyula JN; Bhide SA; Newbold KL; Nutting CM; Harrington KJ
BMC Cancer; 2017 Jan; 17(1):86. PubMed ID: 28143445
[TBL] [Abstract][Full Text] [Related]
11. Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.
Trifiletti DM; Smith A; Mitra N; Grover S; Lukens JN; Cohen RB; Read P; Mendenhall WM; Lin A; Swisher-McClure S
J Clin Oncol; 2017 May; 35(14):1550-1560. PubMed ID: 28475848
[TBL] [Abstract][Full Text] [Related]
12. Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab.
Muñoz C; Caballero M; Hakim S; Verger E; Grau JJ
Eur Arch Otorhinolaryngol; 2016 Aug; 273(8):2193-9. PubMed ID: 26245169
[TBL] [Abstract][Full Text] [Related]
13. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
14. A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck.
Liu H; Gao F; Dahlstrom KR; Li G; Sturgis EM; Zevallos JP; Wei Q; Liu Z
Tumour Biol; 2016 Jun; 37(6):8057-66. PubMed ID: 26711789
[TBL] [Abstract][Full Text] [Related]
15. Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?
Fayda M; Isin M; Tambas M; Guveli M; Meral R; Altun M; Sahin D; Ozkan G; Sanli Y; Isin H; Ozgur E; Gezer U
Tumour Biol; 2016 Mar; 37(3):3969-78. PubMed ID: 26482616
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
17. Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.
Vivenza D; Monteverde M; Lattanzio L; Tonissi F; Astesana V; Denaro N; Comino A; Russi E; Lo Nigro C; Merlano M
Int J Biol Markers; 2016 May; 31(2):e183-92. PubMed ID: 26916894
[TBL] [Abstract][Full Text] [Related]
18. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
Tahara M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
[TBL] [Abstract][Full Text] [Related]
19. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.
Ock CY; Keam B; Lim Y; Kim TM; Lee SH; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
Head Neck; 2016 Feb; 38(2):277-84. PubMed ID: 26104823
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
